Enzalutamide Reduces Oxycodone Exposure in Men with Prostate Cancer

BACKGROUND AND OBJECTIVE: Up to 90% of patients with castration-resistant prostate cancer (CRPC) will develop symptomatic bone metastases requiring pain medication, with opioids being the mainstay of therapy in treating moderate and severe pain. Enzalutamide is an androgen receptor antagonist for th...

Descripción completa

Detalles Bibliográficos
Autores principales: Detert Oude Weme, S. E. H., Hulskotte, L. M. G., Vervenne, W. L., Imholz, A. L. T., Cremers, R. G. H. M., Taxis, K., Reyners, A. K. L., van Berlo-van de Laar, I. R. F., Jansman, F. G. A., Benoist, G. E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338391/
https://www.ncbi.nlm.nih.gov/pubmed/37162620
http://dx.doi.org/10.1007/s40262-023-01255-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338391/
https://www.ncbi.nlm.nih.gov/pubmed/37162620
http://dx.doi.org/10.1007/s40262-023-01255-1

Ejemplares similares